Easing the burden of treatment-resistant depression

Journal of Clinical Psychiatry

Volumn 70, Issue 2, 2009, Pages 273-280

  Fava, Maurizio ^a   Nelson, J Craig ^b   Thase, Michael E ^c   Trivedi, Madhukar H ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APLENZIN; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; LITHIUM; LITHIUM CARBONATE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE;

CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DRUG SUBSTITUTION; ELECTROCONVULSIVE THERAPY; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT HEALTH QUESTIONNAIRE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; QUICK INVENTORY DEPRESSIVE SYMPTOMATOLOGY; REMISSION; REVIEW; TREATMENT FAILURE; ARTICLE; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; DRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; PERSONALITY TEST; PROGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; PSYCHOTHERAPY; RETREATMENT; STATISTICS;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PERSONALITY INVENTORY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PSYCHOMETRICS; PSYCHOTHERAPY; RETREATMENT; TREATMENT FAILURE;

EID: 62649142352     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.8017ah1c     Document Type: Review

References (65)

1. World Health Organization. Depression. www.who.int/mental-health/ management/depression/definition/en/. Updated 2008. Accessed Oct 23, 2008.
2. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475.
3. National Institute of Mental Health. How is depression detected and treated? www.nimh.nih.gov/health/publications/depression/treatment.shtml. Updated Oct 20, 2008. Accessed Oct 23, 2008.
4. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR Publication 93-0551.
5. Rush AJ, Trivedi MH. Treating depression to remission. Psychiatr Ann. 1995;25(12):704-705, 709. (Pubitemid 126006055)
6. Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl. 2002;415:12-17. (Pubitemid 36135480)
7. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504.
8. Murphy JM, Monson RR, Olivier DC, et al. Affective disorders and mortality: a general population study. Arch Gen Psychiatry 1987;44(5):473-480. (Pubitemid 17064492)
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
10. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6(4):278-296.
11. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
13. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
14. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-613. (Pubitemid 32823891)
15. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
16. Souery D, Mendlewicz J. Compliance and therapeutic issues in resistant depression. Int Clin Psychopharmacol. 1998;13(suppl 2):S13-S18. (Pubitemid 28218513)
17. Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62(suppl 6):22-29. (Pubitemid 32298434)
18. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry. 2000;157(suppl 4):1-45. (Pubitemid 30193855)
19. Rush AJ, Trivedi JH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. (Pubitemid 44807782)
20. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. (Pubitemid 43050100)
21. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000;61(6):403-408.
22. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry. 2007;164(5):753-760. (Pubitemid 46808530)
23. Thase ME, Feighner JP, Lydiard RB. Citalopram treatment of fluoxetine nonresponders. J Clin Psychiatry. 2001;62(9):683-687. (Pubitemid 32994930)
24. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57(3):114-115. (Pubitemid 26091473)
25. Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry. 1999;175:12-16. (Pubitemid 29307849)
26. Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol. 2005;25(6):552-560. (Pubitemid 41669048)
27. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64(1):35-39. (Pubitemid 36182227)
28. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord. 1996;39(1):1-6. (Pubitemid 26235318)
29. Quitkin FM, McGrath PJ, Stewart JW, et al. Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Arch Gen Psychiatry. 1990;47(10):935-941. (Pubitemid 20348481)
30. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149(2):195-198.
31. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62(6):413-420. (Pubitemid 32717873)
32. Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003;15(1):17-22. (Pubitemid 36723637)
33. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003;160:237.
34. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion SR, sertraline, or venlafaxine XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
35. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161-1172. (Pubitemid 44464443)
36. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531-1541. (Pubitemid 44465752)
37. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two metaanalyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935-940. (Pubitemid 47015495)
38. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-1622. (Pubitemid 32923653)
39. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848. (Pubitemid 26303624)
40. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530. (Pubitemid 44465751)
41. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-656. (Pubitemid 44772745)
42. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93.
43. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93-102. (Pubitemid 43306504)
44. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry. 1998;155(10):1346-1351. (Pubitemid 28471190)
45. Perez V, Soler J, Puigdemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry. 1999;56(4):375-379. (Pubitemid 29165184)
46. 12 with depression in a middle-aged community sample. Psychol Med. 2005;35(4):529-538.
47. 12, and homocysteine in major depressive disorder, pt 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004;65(8):1090-1095.
48. 12, and homocysteine in major depressive disorder, pt 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004;65(8):1096-1098.
49. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord. 2000;60(2):121-130.
50. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477-479. (Pubitemid 34184747)
51. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056-1061. (Pubitemid 47340326)
52. Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(4):582-587. (Pubitemid 46663041)
53. Nelson J, Mazure C, Jatlow P, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300. (Pubitemid 38117167)
54. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22(4):379-387. (Pubitemid 34810327)
55. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-188. (Pubitemid 34127908)
56. Blier P, Gobbi G, Turcotte JE, et al. A double-blind prolongation study of the combined treatment of depression with mirtazapine and paroxetine. Presented at the 43rd annual meeting of the New Clinical Drug Evaluation Unit; May 27-30, 2003; Boca Raton, Fla.
57. Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826-831. (Pubitemid 47015480)
58. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236. (Pubitemid 46362643)
59. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med. 2007;147(9):593-602.
60. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, nonpsychotic major depression. J Psychiatr Res. 2008; Available online ahead of print 30 June 2008.
61. Rapaport MH, Gharabawi GM, Canuso CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology. 2006;31(11):2505-2513. (Pubitemid 44607069)
62. Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65(2):217-221.
63. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry. 2004;65(7):975-981.
64. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. (Pubitemid 47015482)
65. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28(2):156-165.